News Trump pulls Biden policies on health insurance, drug pricing President Trump has started dismantling health legislation introduced under the Biden administration on day one of his new term.
News FTC doubles down on PBM criticism in new report A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.
News PBM reform dropped in Congress' funding package Proposed reforms to the regulations for PBMs were dropped from the US Congress' end-of-year bill to provide funding to the federal government.
News PBM reform looms in end-of-year US legislation package Legislation that would introduce big changes for pharmacy benefit managers (PBMs) is inching closer to realisation in the US Congress.
News ICER identifies new crop of 'unsupported' drug price rises Gilead Sciences, Johnson & Johnson, Novartis, Exelixis, and Pfizer have been taken to task by ICER for price increases without new clinical evidence.
Market Access Part Two: Navigating the complexities of global market acces... The journey to global market access for innovative therapies is fraught with challenges that vary significantly across the world.
Oncology JP Morgan Week 2025 – Marianne De Backer At JPM 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl